← Compound index
COMPOUND RECORD / VISOLUTEN

VisolutenВизолутен

A peptide mixture from calf or pig eye tissue, studied in a Russian report on vision and retinal function.

Source linked

What the studies found

Comparison in people · 2011

Visoluten: institute clinical report (commercially hosted translation)

The report describes visual-acuity and retinal electrophysiology changes during adjunctive care.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 49 patients: 29 adjunctive preparation, 20 conventional-care controls

Important limitations

  • Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated. Random division is asserted without sequence or concealment details. Percentages and eye-versus-patient denominators need original data. Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.

Institute-attributed report, 2011; commercially hosted brochure pp. 17–19 · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Visoluten

Identity / background source ↗

Research background

Visoluten is an ocular peptide preparation. A Medical Center report assessed visual outcomes during adjunctive care.

Compound class
Archival preparation lead
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

49 patients: 29 adjunctive preparation, 20 conventional-care controls

Study methods

Small adjunctive comparison; signed original, allocation and reporting require verification

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

New indexed primary abstracts and/or report reproductions linked; review depth shown per source

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2011

Visoluten: institute clinical report (commercially hosted translation)

The report describes visual-acuity and retinal electrophysiology changes during adjunctive care.

Study notes and original source
2011Human comparative studyFull text available

Visoluten: institute clinical report (commercially hosted translation)

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

Format: PDF · Reviewed: Report reproduction reviewed

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 17–19

The report describes visual-acuity and retinal electrophysiology changes during adjunctive care.

Population / setting
49 patients: 29 adjunctive preparation, 20 conventional-care controls
Source reviewed
Brochure PDF pp. 17–19: methods/results text checked; selected population/table pages visually inspected. This is a provenance check, not authentication of the institute original.
Study limitations
  • Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
  • Random division is asserted without sequence or concealment details. Percentages and eye-versus-patient denominators need original data.
  • Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.

Reviewed 2026-10-05.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗